MISHC Data On Quality of Life After Mitral Valve Transcatheter Edge-to-edge Repair According to Baseline Tricuspid Regurgitation Severity Presented at New York Valves 2024
Collin Brooks, MD presented "Quality of Life After Mitral Valve Transcatheter Edge-to-edge Repair According to Baseline Tricuspid Regurgitation Severity" during New York Valves: The Structural Heart Summit 2024 in New York City, held June 5th – 7th.
There is a high prevalence of significant tricuspid regurgitation (TR) in patients undergoing Mitral Transcatheter Edge-to-Edge Repair (M-TEER) and concomitant TR is associated with increased mortality, hospitalizations, and symptomatic burden; also seen in M-TEER patients. Randomized control trials of tricuspid valve therapy have only shown improvements in quality of life to date.
Dr. Brooks and co-authors Neal Duggal, MD; Milan Seth, MS; Megan Joseph, MD; and Andrew Harris, MD aimed to evaluate the effect of baseline TR on quality-of-life outcomes in M-TEER.
A review of MISHC data found that regardless of TR severity in patients undergoing Transcatheter Edge-to-Edge Repair, on average patients experienced a large improvement in quality of life. Moderate/severe TR was associated with reduced quality of life and survival.
Further research should explore a staged approach of M-TEER followed by tricuspid valve intervention compared to concomitant mitral/tricuspid valve surgery.